Vivani Medical, Inc. - Common Stock (NQ:VANI)

1.301 +0.001 (+0.08%)

Streaming Delayed Price Updated: 10:01 AM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Volume	8,166,930
Open	1.320
Bid (Size)	1.300 (1,400)
Ask (Size)	1.310 (1,300)
Prev. Close	1.300
Today's Range	1.290 - 1.370
52wk Range	0.9228 - 1.920
Shares Outstanding	54,978,465
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Today 7:35 EDT

Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani

From Vivani Medical, Inc.

Via GlobeNewswire

Vivani Medical Inc (NASDAQ:VANI) Reports Q4 2025 Results, Advances Semaglutide Implant to Phase 1 ↗

March 26, 2026

Via Chartmill

Performance

YTD	+2.4%	+2.4%
1 Month	+13.1%	+13.1%
3 Month	+17.2%	+17.2%
6 Month	+3.3%	+3.3%
1 Year	+2.4%	+2.4%

More News

Vivani Medical, Inc. Announces Closing of Common Stock Offering

January 27, 2026

From Vivani Medical, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 17, 2025

Via Benzinga

Which stocks are experiencing notable movement on Wednesday? ↗

September 17, 2025

Via Chartmill

Discover the top movers in Wednesday's pre-market session. ↗

September 17, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data ↗

August 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 13, 2025

Via Benzinga

EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs ↗

April 15, 2025

Via Benzinga

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars ↗

March 26, 2025

Via Stocktwits

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing ↗

March 26, 2025

Via Benzinga

Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

March 24, 2025

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

March 13, 2025

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗

March 13, 2025

Via Benzinga

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

March 12, 2025

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value ↗

March 12, 2025

Via Benzinga

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

December 19, 2024

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia ↗

December 19, 2024

Via Benzinga

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

December 04, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

November 13, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

October 22, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

September 26, 2024

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia ↗

September 26, 2024

Via Benzinga

Frequently Asked Questions

Is Vivani Medical, Inc. - Common Stock publicly traded?

Yes, Vivani Medical, Inc. - Common Stock is publicly traded.

What exchange does Vivani Medical, Inc. - Common Stock trade on?

Vivani Medical, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vivani Medical, Inc. - Common Stock?

The ticker symbol for Vivani Medical, Inc. - Common Stock is VANI on the Nasdaq Stock Market

What is the current price of Vivani Medical, Inc. - Common Stock?

The current price of Vivani Medical, Inc. - Common Stock is 1.301

When was Vivani Medical, Inc. - Common Stock last traded?

The last trade of Vivani Medical, Inc. - Common Stock was at 07/07/26 10:01 AM ET

What is the market capitalization of Vivani Medical, Inc. - Common Stock?

The market capitalization of Vivani Medical, Inc. - Common Stock is 71.53M

How many shares of Vivani Medical, Inc. - Common Stock are outstanding?

Vivani Medical, Inc. - Common Stock has 72M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.